GlassScriptPhysician profile
Vidhya Kunnathur
NPI 1477715647
$95,846.30
in general payments reported to CMS, 2019-2025
17 companies · $30K in 2025
The $30K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $48.56 · 2021: $231 · 2022: $13K · 2023: $17K · 2024: $35K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Consulting Fee: $8,376 · Travel and Lodging: $6,770 · Food and Beverage: $4,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,131.66 |
| Consulting Fee | $8,376.00 |
| Travel and Lodging | $6,770.19 |
| Food and Beverage | $4,317.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $59,897.07 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $28,886.01 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $4,789.06 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $967.04 | 2020-2025 | |
| Qol Medical, LLC | $516.51 | 2022-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $343.21 | 2019-2025 | Tremfya, Stelara |
| Ironwood Pharmaceuticals, INC | $163.23 | 2021-2025 | |
| Lilly USA, LLC | $70.18 | 2024 | Omvoh |
| Organon LLC | $50.93 | 2024-2025 | Renflexis, Hadlima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.19 | 2023 | Xifaxan |
| Ucb, INC. | $34.33 | 2019 | |
| Pfizer INC. | $28.19 | 2022 | |
| Shire North American Group INC | $20.97 | 2019 | |
| Celgene Corporation | $19.39 | 2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $13.99 | 2023 | Clenpiq |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidhya Kunnathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.